Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | TAS2940 |
| Synonyms | |
| Therapy Description |
TAS2940 is a brain-penetrant inhibitor of EGFR and ERBB2 (HER2), potentially leading to decreased tumor cell proliferation and inhibition of tumor growth (PMID: 36282234). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| TAS2940 | TAS 2940|TAS-2940 | EGFR Inhibitor (Pan) 63 HER2 Inhibitor 44 | TAS2940 is a brain-penetrant inhibitor of EGFR and ERBB2 (HER2), potentially leading to decreased tumor cell proliferation and inhibition of tumor growth (PMID: 36282234). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04982926 | Phase I | TAS2940 | A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer | Terminated | USA | FRA | 0 |